Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation

Korean Journal of Internal Medicine

Volumn 29, Issue 5, 2014, Pages 630-636

  Park, Joo Han ^a   Lee, Hyo Jung ^a   Kim, Sei Rhan ^a   Song, Ga Won ^a   Lee, Seung Kyong ^a   Park, Sun Young ^a   Kim, Ki Chan ^a   Hwang, Sun Hyuk ^a   Park, Joon Seong ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Graft vs host disease; Stem cell transplantation; TNFR Fc fusion protein

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FLUDARABINE; GANCICLOVIR; METHOTREXATE; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMINAL ABSCESS; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANDIDEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROPATHY; ESOPHAGITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LIVER DISEASE; LUNG INFECTION; MALE; MENINGITIS; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; REDUCED INTENSITY CONDITIONING; REMISSION; RETROSPECTIVE STUDY; SKIN DISEASE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; ACUTE DISEASE; ADVERSE EFFECTS; AGED; ALLOGRAFT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; ALLOGRAFTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; STEROIDS; YOUNG ADULT;

EID: 84907152981     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2014.29.5.630     Document Type: Article

References (17)

1. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8:387-394.
2. Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008;111:2470-2475.
3. Kim DH, Sohn SK, Baek JH, et al. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 2005;113:220-227.
4. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990;75:1024-1030.
5. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998;22:61-65.
6. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8:155-160.
7. Markey KA, Burman AC, Banovic T, et al. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood 2010;115:122-132.
8. Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:680-687.
9. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
11. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007;137:87-98.
12. Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35:1003-1010.
13. Maeda Y, Levy RB, Reddy P, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 2005;105:2023-2027.
14. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992;79:3362-3368.
15. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-4055.
16. Mollee P, Morton AJ, Irving I, Durrant S. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol 2001;113:217-223.
17. Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/-mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006;37:1143-1147.